Trends in Patient Outcome Scores in Orthopaedic Oncology: A Systematic Review
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INTRODUCTION

• The field of orthopaedic oncology has
trailed in defining trends in reported
outcome measures (ROMs) over the last
decade
• The Musculoskeletal Tumor Society
Score (MSTS) is a well-recognized ROM
• New ROMs developed and established
in literature have created difficulty in
identifying the standard ROM within the
field
• The aim of our study is to identify trends
in the use of ROMs in orthopaedic
oncology over time, as well as frequency
and distribution among specific
pathologies and orthopaedic journals
METHODS

• We conducted a systematic review of all
original topics relating to orthopaedic
oncology in five orthopaedic journals over
a ten-year period (2011-2021)
• A total of 13,756 articles were published in
the five journals over the period from
2011-2021
• 2,357 articles had a title indicating clinical
focus on an orthopaedic oncological topic,
pathological condition, or procedure
• A total of 197 articles had at least one
clinical outcome rating instrument
• The ROM used in all articles was
recorded, in addition to study date, study
design, clinical topic/pathology, and level
of evidence
• The Cochran Armitage Test of Trend was
used to determine significance in trends
for each ROM.
• Significance was specified at a p value of
<.05
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RESULTS

DISCUSSION
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• Out of 2,315 musculoskeletal tumor
focused articles reviewed, 197 (8.5%)
articles included at least one clinical
outcome rating instrument
• The most popular tools used were the
MSTS (57%) and the Toronto Extremity
Salvage (TESS) Score (12.5%), followed
by the 36-Item Short Form (SF-36)
Survey (5.1%), and Patient Reported
Outcomes Measurement Information
System (PROMIS) (3.1%)
• Of the five journals, CORR comprised
the greatest proportion of outcome
articles (45.7%), followed by BJJ
(28.1%), JBJS (14.1%), Sarcoma
(11.6%), and ORS (.5%)
• In CORR, MSTS was used in 77 different
articles (65.81%) of all outcome
measures used , followed by TESS
(12.8%), SF-36 (5.1%), PROMIS (3.4%),
and Disabilities of the arm, shoulder, and
hand (DASH) score (3.4%)
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Figure 2 – Proportion of articles in which the top four patient
reported outcome measures (PROMs) appeared at least
once throughout a ten-year period (2011-2021). Regression
analysis and data are included (*= p < 0.05)

• MSTS was consistently used the most
over the last decade, but its use has
steadily decreased approximately 2.5%
(R2 = 0.28, p = 0.2) each year
• PROMIS has been trending positively
over the past few years, with an increase
at a rate of .9% (R2 = 0.28, p = 0.02)
• The rate of use of TESS and SF-36 have
slightly decreased over the last decade
with a decrease in .5% (R2 = 0.02, p= .1)
and .6% (R2 = 0.12, p = 0.08)
respectively
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• Our data suggests that MSTS is the
most widely used outcome tool across
the five journals that we reviewed
• It was not only the most used, but the
frequency of its use was far greater than
any other outcome tool
• Although there seems to be a positive
trend in the use of PROMIS, future data
would be needed to determine if
PROMIS would surpass MSTS in its use
• Approximately 25 different outcome
scales were identified during our review,
indicating there has yet to be consensus
on a “gold standard” for measuring
PROMs in orthopaedic oncology
• Orthopaedic oncology continues to trail
significantly behind other medical and
surgical fields when it comes to
standardizing measurement of outcomes
• Interventions performed by orthopedic
oncologists tend to be particularly
morbid, thus the lag in standardization is
concerning
• As data reflects, PROMIS is slowly being
accepted in the community, and its
consideration will broaden the definition
of patient outcome and treatment
success due to its extent of questioning.
• We propose the use of PROMIS
concurrently with another functional
outcome measure, as it will provide a
more thorough perspective of patients’
overall outcome.
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